Samsung Biologics proposed its largest-ever acquisition, launching an all-cash tender offer to buy PolyPeptide Group, a CDMO specializing in peptide-based APIs. The company offered CHF 44.31 per share for full ownership of PolyPeptide, positioning the deal as a modality expansion beyond antibodies and ADCs. Samsung framed PolyPeptide as strategic for meeting growing demand for peptide therapeutics, including GLP-1-related programs, and for strengthening global development-to-commercial manufacturing capabilities. PolyPeptide’s integrated model and international site footprint are expected to help Samsung accelerate service capacity in peptide development. The planned acquisition also signals how contract manufacturing is reorganizing to serve high-growth peptide pipelines as obesity and metabolic franchises expand.